This is a working overview of GHRH analog, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-11 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
=== Melanotan peptide hormones === The role of alpha-melanocyte-stimulating hormone (α-MSH) in promoting melanin diffusion has been known since the 1960s. In the 1980s, scientists at University of Arizona began attempting to develop α-MSH and analogs as potential sunless tanning agents, and synthesized and tested several analogs, including afamelanotide, then called melanotan-I. In the European Union and United States, afamelanotide is indicated for the prevention of phototoxicity in adults with erythropoietic protoporphyria. Afamelanotide is also being investigated as a method of photoprotection from in the treatment of polymorphous light eruption, actinic keratosis and squamous cell carcinoma (a form of skin cancer). Bremelanotide is used for the treatment of generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. To pursue the tanning agent, melanotan-I was licensed by Competitive Technologies, a technology transfer company operating on behalf of University of Arizona, to an Australian startup called Epitan, which changed its name to Clinuvel in 2006. A number of products are sold online and in gyms and beauty salons as "melanotan" or "melanotan-1" which discuss afamelanotide in their marketing. The products are not legal in any jurisdiction and are dangerous. Starting in 2007 health agencies in various counties began issuing warnings against their use.
== Diagnosis == Hypophosphatemia is diagnosed by measuring the concentration of phosphate in the blood. Concentrations of phosphate less than 0.81 mmol/L (2.5 mg/dL) are considered diagnostic of hypophosphatemia, though additional tests may be needed to identify the underlying cause of the disorder.
On 22 February, however, a Save the Children representative stated, "Even if the war were to end tomorrow, education can not just resume. More than half of Gaza's schools have either been destroyed or are too damaged to even function". In August 2024, UNRWA launched a "back to learning programme" in Khan Younis. In August 2024, the Education Cluster, Save the Children, and UNICEF stated that students and children in Gaza had lost a year of education and warned that the "majority of them may never return to school again". Some students enrolled in online classes or learned in tent classrooms. As of January 2025, children in Gaza had been without formal schooling for over a year. While some informal classes reportedly take place in displacement camps, parents say their children are falling behind academically, forgetting basic literacy skills, or losing crucial years of education altogether.
There are a few slightly more common diagnoses such as pulmonary hypoplasia, cryptorchidism, congenital heart defects, tracheoesophageal fistulas, inguinal hernias, cleft palate, and eye abnormalities.
Sources: en.wikipedia.org
6 November A PAVN sapper attack on Firebase St. George occupied by the 1st Battalion, 14th Infantry and 1st Battalion, 9th Artillery resulted in nine U.S. killed. MACV announced that it was holding back on sending U.S. ground forces to reinforce Duc Lap Camp as a test of the ARVN's abilities to handle higher intensity combat. The House Foreign Affairs Committee approved a resolution supporting Nixon's Vietnam policy.
=== Divisions === The Scientific Division works to advance the science of clinical chemistry and to apply it to the practice of clinical laboratory medicine. It is responsible for responding to the scientific and technical needs of IFCC member societies, IFCC corporate members and external agencies. It instigates and promotes theoretical and practical developments in the field of standards and standardization in clinical chemistry. The Education and Management Division provides IFCC members and the health-care community with education relevant to clinical chemistry and laboratory medicine. It administers a visiting lecturer program as well as clinical courses and workshops in molecular biology and other specialized areas. The Communications and Publications Division promotes the work of the IFCC to scientists, physicians, and global health policy makers. It also publishes the academic journal eJIFCC. The Emerging Technologies Division identifies new technologies that could be applied to laboratory medicine and explores applications for those technologies.
== External links == IUPAC's "Glossary of Terms Used in Combinatorial Chemistry" ACS Combinatorial Science (formerly Journal of Combinatorial Chemistry) Combinatorial Chemistry Review "Molecular Diversity". metapress.com. Archived from the original on May 15, 2016. Combinatorial Chemistry and High Throughput Screening Combinatorial Chemistry: an Online Journal SmiLib - A free open-source software for combinatorial library enumeration GLARE - A free open-source software for combinatorial library design
Meat floss, also known as yuk sung or rousong (Chinese: 肉鬆; pinyin: ròusōng; Jyutping: juk6 sung1; Mandarin Chinese: [ɻôʊsʊ́ŋ]), is a dried meat product of Chinese origin, with a light and fluffy texture similar to coarse cotton. It is more commonly known as bak hu (Hokkien: 肉拊, Pe̍h-ōe-jī: bah-hú) in Hokkien-influenced regions, such as Southeast Asia and Taiwan. Meat floss is golden in color with a distinctive flavor and sweet taste that is somewhat comparable to beef jerky.
Natural Selection is a modification for the video game Half-Life. Its concept is a mixture of the first-person shooter and real-time strategy game genres. The game was created by Charlie "Flayra" Cleveland, who later founded the company Unknown Worlds Entertainment. Natural Selection v1 was first publicly released on Halloween 2002, and is now at version 3.2. Natural Selection 2 was released in late 2012. The game features two teams: Kharaa (alien species) and Frontiersmen (human space marines). The visible Kharaa "units" are actually simply the spawn of the real Kharaa (aliens) which are microscopic life-forms according to the storyline. The game was, in 2008, one of the ten most played Half-Life modifications in terms of players, according to GameSpy. On January 22, 2014 Unknown Worlds released the source code for download on a GitHub repository under GPLv3.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.